Literature DB >> 22023017

Biased signalling and allosteric machines: new vistas and challenges for drug discovery.

Terry P Kenakin1.   

Abstract

Seven transmembrane receptors (7TMRs) are nature's prototype allosteric proteins made to bind molecules at one location to subsequently change their shape to affect the binding of another molecule at another location. This paper attempts to describe the divergent 7TMR behaviours (i.e. third party allostery, receptor oligomerization, biased agonism) observed in pharmacology in terms of a homogeneous group of allosteric behaviours. By considering the bodies involved as a vector defined by a modulator, conduit and guest, these activities can all be described by a simple model of functional allostery made up of the Ehlert allosteric model and the Black/Leff operational model. It will be shown how this model yields parameters that can be used to characterize the activity of any ligand or protein producing effect through allosteric interaction with a 7TMR.
© 2011 The Author. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Mesh:

Substances:

Year:  2012        PMID: 22023017      PMCID: PMC3372820          DOI: 10.1111/j.1476-5381.2011.01749.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

1.  Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor.

Authors:  R M Krause; B Buisson; S Bertrand; P J Corringer; J L Galzi; J P Changeux; D Bertrand
Journal:  Mol Pharmacol       Date:  1998-02       Impact factor: 4.436

2.  Agonist efficacy and allosteric models of receptor action.

Authors:  H O Onaran; T Costa
Journal:  Ann N Y Acad Sci       Date:  1997-05-30       Impact factor: 5.691

3.  The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy.

Authors:  J M Weiss; P H Morgan; M W Lutz; T P Kenakin
Journal:  J Theor Biol       Date:  1996-08-21       Impact factor: 2.691

4.  Anti-muscarinic toxins from Dendroaspis angusticeps.

Authors:  J S Liang; J Carsi-Gabrenas; J L Krajewski; J M McCafferty; S L Purkerson; M P Santiago; W L Strauss; H H Valentine; L T Potter
Journal:  Toxicon       Date:  1996 Nov-Dec       Impact factor: 3.033

5.  Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods.

Authors:  F J Ehlert
Journal:  Mol Pharmacol       Date:  1988-02       Impact factor: 4.436

6.  Operational models of pharmacological agonism.

Authors:  J W Black; P Leff
Journal:  Proc R Soc Lond B Biol Sci       Date:  1983-12-22

Review 7.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Authors:  T Kenakin
Journal:  Trends Pharmacol Sci       Date:  1995-07       Impact factor: 14.819

8.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model.

Authors:  P Samama; S Cotecchia; T Costa; R J Lefkowitz
Journal:  J Biol Chem       Date:  1993-03-05       Impact factor: 5.157

9.  A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones.

Authors:  J N Kew; G Trube; J A Kemp
Journal:  J Physiol       Date:  1996-12-15       Impact factor: 5.182

10.  Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes.

Authors:  J Ellis; J Huyler; M R Brann
Journal:  Biochem Pharmacol       Date:  1991-10-24       Impact factor: 5.858

View more
  91 in total

1.  Themed section: molecular pharmacology of GPCRs.

Authors:  R J Summers
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  The mass action equation in pharmacology.

Authors:  Terry Kenakin
Journal:  Br J Clin Pharmacol       Date:  2015-12-21       Impact factor: 4.335

Review 3.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

4.  Mutations in arrestin-3 differentially affect binding to neuropeptide Y receptor subtypes.

Authors:  Luis E Gimenez; Stefanie Babilon; Lizzy Wanka; Annette G Beck-Sickinger; Vsevolod V Gurevich
Journal:  Cell Signal       Date:  2014-03-29       Impact factor: 4.315

5.  Structural signatures of DRD4 mutants revealed using molecular dynamics simulations: Implications for drug targeting.

Authors:  Nidhi Jatana; Lipi Thukral; N Latha
Journal:  J Mol Model       Date:  2015-12-17       Impact factor: 1.810

6.  Ligand- and cell-dependent determinants of internalization and cAMP modulation by delta opioid receptor (DOR) agonists.

Authors:  Iness Charfi; Karim Nagi; Ouissame Mnie-Filali; Dominic Thibault; Gianfranco Balboni; Peter W Schiller; Louis-Eric Trudeau; Graciela Pineyro
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

Review 7.  Proteinases, their receptors and inflammatory signalling: the Oxford South Parks Road connection.

Authors:  M D Hollenberg
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

Review 8.  Gaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessors.

Authors:  Terry Kenakin
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

Review 9.  Beyond traditional pharmacology: new tools and approaches.

Authors:  E V Gurevich; V V Gurevich
Journal:  Br J Pharmacol       Date:  2015-06-10       Impact factor: 8.739

Review 10.  Molecular and cellular analysis of human histamine receptor subtypes.

Authors:  Roland Seifert; Andrea Strasser; Erich H Schneider; Detlef Neumann; Stefan Dove; Armin Buschauer
Journal:  Trends Pharmacol Sci       Date:  2012-12-17       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.